Plasma-Seq follow-up CSPC4
We performed serial plasma-Seq analyses on a male who progressed from castration-sensitive to castration-resistant prostate cancer within 10 months following treatment with androgen-deprivation therapy.
- 27/05/2015
- 2 samples
- DAC: EGAC00001000072
- Technology: Illumina MiSeq
CTC - Plasma-DNA - MONDO:0008315
European Genome-Phenome Archive c/o European Bioinformatics Institute Wellcome Trust Genome Campus Hinxton Cambridge CB10 1SD United Kingdom To whom it may concern, This document refers to datasets specific for MONDO:0008315 which has been submitted to the European Genome Archive (EGA) for the restricted access by legitimate academic institutions that have agreed to comply with the terms of a Data Access Agreement drafted by Ellen Heitzer. There are a number of steps that a researcher must take to obtain access to this data and the process is overseen by Ellen Heitzer Ellen Heitzer is a Postdoctoral Fellow and is authorized to approve researchers to have encrypted access to the data submitted to the EGA. Please be advised that Ellen Heitzer (ellen.heitzer@medunigraz.at) is authorized to upload data to the EGA for archiving and distribution as part of your submission process, which will enable approved researchers to have encrypted access to the data. We can confirm that this submission is consistent with the informed consent of the participants of the study or has been granted ethical approval and is in accordance with the applicable laws and regulations. Sincerely, Michael R. Speicher Principle Investigator
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
| Study ID | Study Title | Study Type |
|---|---|---|
| EGAS00001000451 | Other |